Minerva reports Q3 EPS ($1.03) vs. ($1.29) last year

“We remain committed to bringing roluperidone to patients and physicians as we believe it addresses a significant unmet clinical need and has the potential to improve patients’ quality of life and expand treatment options available to physicians. If approved, roluperidone would be the first medication for negative symptoms of schizophrenia to receive regulatory approval,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.